Investor Presentaiton slide image

Investor Presentaiton

Sintilimab: Clinical Development Programs 4 indications approved, 1 sNDA under review in China, BLA accepted in US INDICATION China r/r Classical Hodgkin's Lymphoma 1L Non-squamous NSCLC 1L Squamous NSCLC 1L Hepatocellular Carcinoma 2L Squamous NSCLC EGFR+ TKI Failure NCSLC (MRCT) 1L Gastric Cancer 1L Gastric Cancer (CPS ≥10) 1L Esophageal Carcinoma (MRCT) 2L Classical Hodgkin's Lymphoma Melanoma (adjuvant) 1L Hepatocellular Carcinoma 2L Hepatocellular Carcinoma 2L/+ Cervical cancer 2L ESCC r/r NK/T-cell Lymphoma 3L CRC Refractory Gastrointestinal Cancer 1L Gastric Cancer MONO-/COMBO-THERAPY (OTHER COMPONENTS) Mono Combo (pemetrexed and cisplatin) Combo (gemcitabine and platinum) Combo (IBI-305/biosimilar to bevacizumab) Mono Combo (IBI-305/biosimilar to bavecizumab) Combo (capecitabine and oxaliplatin) Combo (Ramucizumab) Combo (paclitaxel and cisplatin/5-FU and cisplatin) Combo (ICE) Combo (IBI-310/CTLA-4 mAb) Combo (IBI-310/CTLA-4 mAb) Combo (IBI-310/CTLA-4 mAb) Combo (IBI-310/CTLA-4 mAb) Mono Mono Combo (IBI-310/CTLA-4 mAb) Mono 2L NSCLC 1L/2L Melanoma Combo (capecitabine and oxaliplatin) Mono Mono Combo (gemcitabine and cisplatin) 1L Squamous NSCLC 1L/2L Neuroendocrine Tumor Solid Tumors/colorectal cancer Solid Tumors/cholangiocarcinoma 3L colorectal cancer 2L Hepatocellular Carcinoma U.S. 1L Non-squamous NSCLC 1L Esophageal Carcinoma (MRCT) Solid Tumors Combo (EP/IP) Combo (Fruquintinib) Combo (Surufatinib) Combo (Chidamide) Combo (siRNA) Combo (pemetrexed and cisplatin) Combo (paclitaxel and cisplatin/5-FU and cisplatin) STATUS 1A 1B PHASE 2 PHASE 3 NDA FILED NDA APPROVED Mono Late Stage Endometrial Carcinoma Mono Symbols: = completed; = completed patient enrollment; ①= in progress; = to be initiated within next quarter.
View entire presentation